Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126890
Title: | The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
Author: | Dinges, Warren Girard, Pierre-Marie Podzamczer Palter, Daniel Brockmeyer, Norbert H. García, Felipe Harrer, Thomas Lelievre, Jean-Daniel Frank, Ian Colin De Verdiere, Nathalie Yeni, Guy-Patrick Ortega Gonzalez, Enrique Rubio, Rafael Clotet, Bonaventura, 1953- DeJesus, Edwin Pérez Elías, María Jesús Launay, Odile Pialoux, Gilles Slim, Jihad Weiss, Laurence Bouchaud, Olivier Felizarta, Franco Meurer, Anja Raffi, François Esser, Stefan Katlama, Christine Koletar, Susan L. Mounzer, Karam Swindells, Susan Baxter, John Schneider, Stefan Chas, Julie Molina, Jean-Michel Koutsoukos, Marguerite Collard, Alix Bourguignon, Patricia Roman, François |
Keywords: | VIH (Virus) Vacunes HIV (Viruses) Vaccines |
Issue Date: | Feb-2016 |
Publisher: | Lippincott Williams & Wilkins |
Abstract: | The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults.This phase IIb, observer-blind study (NCT01218113), included ART-naive HIV-1 infected adults aged 18 to 55 years. Participants were randomized to receive 2 (F4/AS01(B)_2 group, N=64) or 3 (F4/AS01(B)_3 group, N=62) doses of F4/AS01(B) or placebo (control group, N=64) at weeks 0, 4, and 28. Efficacy (HIV-1 VL, CD4(+) T-cell count, ART initiation, and HIV-related clinical events), safety, and immunogenicity (antibody and T-cell responses) were evaluated during 48 weeks.At week 48, based on a mixed model, no statistically significant difference in HIV-1 VL change from baseline was demonstrated between F4/AS01(B)_2 and control group (0.073 log(10)copies/mL [97.5% confidence interval (CI): -0.088; 0.235]), or F4/AS01(B)_3 and control group (-0.096 log(10)copies/mL [97.5% CI: -0.257; 0.065]). No differences between groups were observed in HIV-1 VL change, CD4(+) T-cell count, ART initiation, or HIV-related clinical events at intermediate timepoints. Among F4/AS01(B) recipients, the most frequent solicited symptoms were pain at injection site (252/300 doses), fatigue (137/300 doses), myalgia (105/300 doses), and headache (90/300 doses). Twelve serious adverse events were reported in 6 participants; 1 was considered vaccine-related (F4/AS01(B)_2 group: angioedema). F4/AS01(B) induced polyfunctional F4-specific CD4(+) T-cells, but had no significant impact on F4-specific CD8(+) T-cell and anti-F4 antibody levels.F4/AS01(B) had a clinically acceptable safety profile, induced F4-specific CD4(+) T-cell responses, but did not reduce HIV-1 VL, impact CD4(+) T-cells count, delay ART initiation, or prevent HIV-1 related clinical events. |
Note: | Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000002673 |
It is part of: | Medicine, 2016, vol. 95, num. 6 |
URI: | http://hdl.handle.net/2445/126890 |
Related resource: | https://doi.org/10.1097/MD.0000000000002673 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
DingesW.pdf | 636.62 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License